Galena Will Adjourn Special Meeting until Friday, December 29, 2017, Urges Stockholders to Vote

SAN RAMON, Calif., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), (“Galena”) announced today that its special meeting of stockholders (“Special Meeting”), scheduled for December 15, 2017, will be convened and adjourned, without any business being conducted, in order to allow sufficient time for stockholders to vote based upon a change in information … [Read more...]

iKang Announces Unaudited Financial Results for the Fiscal Second Quarter Ended September 30, 2017

BEIJING, Dec. 14, 2017 (GLOBE NEWSWIRE) -- iKang Healthcare Group, Inc. (“iKang” or the “Company”) (Nasdaq:KANG), a major provider in China’s fast growing private preventive healthcare services market, today announced its unaudited financial results for the fiscal second quarter ended September 30, 2017. Fiscal Second Quarter Ended September 30, 2017 Financial Highlights … [Read more...]

BioDelivery Sciences Reacquires ONSOLIS® from Collegium Pharmaceutical

RALEIGH, N.C., Dec. 14, 2017 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced that it has received the required 90-day notice from Collegium Pharmaceutical, Inc. regarding termination of the license and development agreement for ONSOLIS® (fentanyl buccal soluble film) between BDSI and Collegium.    BDSI and Collegium entered into a license … [Read more...]

Wright Medical Group N.V. Announces Acquisition of IMASCAP SAS

Ensures Exclusive Access to Breakthrough Software Enabling Technology to Further Differentiate Wright’s Product Portfolio and Further Accelerate Growth Opportunities in Wright’s Global Extremities Business Purchase Price of €75.1 Million, or Approximately $88.8 Million, in Cash, Stock and Earnouts Company Reiterates Previously Provided 2017 Annual Financial Guidance … [Read more...]

Spero Therapeutics Announces 3Q17 Operating Results and Pipeline Update

Raised approximately $83.6 million in gross proceeds from Initial Public OfferingAdvanced pipeline with initiation of SPR994 Phase 1 trial in October 2017 and SPR741 Phase 1b trial in November 2017 CAMBRIDGE, Mass., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, … [Read more...]